Development and optimization of enzalutamide nanosuspension by design of experiments for dissolution enhancement
Abstract
Enzalutamide is an anticancer molecule used for prostate cancer. The goal of the study was to develop a nanosuspension of enzalutamide in order to improve its solubility and dissolution properties. High speed homogenization method was employed to formulate the nanosuspension. Preliminary studies suggested amount of stabilizer, homogenization time and homogenization speed as critical variables to be taken for the optimization process. Box-Behnken design was employed for the optimization of process and formulation variables. Nanosuspension was evaluated for particle size, PDI, zeta potential, and in vitro drug release at 10 min (D10) studies. Regression analysis suggested the influence of independent variables on the responses. The optimized batch obtained from overlay plot exhibited 198.36 nm of particle size, (-33.27 mV of zeta potential and 80.47 % of D10 values. The characterization studies i.e. DSC, and XRD illustrated retention in crystallinity of drug. The drug and formulation were found to be stable over a 6-month period in accelerated stability testing. Using high speed homogenization method, particle size of the formulation was reduced to nano-size which was further responsible for the improvement in dissolution and bioavailability of drug.
Keywords:
ENZALUTAMIDE, NANOSUSPENSION, NANOCRYSTALS, DISSOLUTION ENHANCEMENT, QUALITY BY DESIGNDOI
https://doi.org/10.25004/IJPSDR.2023.150604References
Papich MG, Martinez MN. Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls. AAPS J. 2015;17(4):948-64.
Khan A, Iqbal Z, Shah Y, Ahmad L, Ismail, Ullah Z, Ullah A. Enhancement of dissolution rate of class II drugs (Hydrochlorothiazide); a comparative study of the two novel approaches; solid dispersion and liqui-solid techniques. Saudi Pharm J. 2015;23(6):650-7.
Al-Kazemi R, Al-Basarah Y, Nada A. Dissolution Enhancement of Atorvastatin Calcium by Cocrystallization. Adv Pharm Bull. 2019;9(4):559-570.
Boyd BJ, Bergström CAS, Vinarov Z, Kuentz M, Brouwers J, Augustijns P, et al. Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. Eur J Pharm Sci. 2019;137:104967.
Paul A. Drug Absorption and Bioavailability. In: Raj G, Raveendran R. (eds) Introduction to Basics of Pharmacology and Toxicology. Springer, Singapore, 2019.
Jain S, Patel N, Lin S. Solubility and dissolution enhancement strategies: current understanding and recent trends. Drug Dev Ind Pharm. 2015;41(6):875-887.
Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012;2012:195727.
Kumar R, Thakur AK, Chaudhari P, Banerjee N. Particle Size Reduction Techniques of Pharmaceutical Compounds for the Enhancement of Their Dissolution Rate and Bioavailability. J Pharm Innov. 2022;17, 333-352.
Eesam S, Bhandaru JS, Naliganti C, Bobbala RK, Akkinepally RR. Solubility enhancement of carvedilol using drug–drug cocrystallization with hydrochlorothiazide. Futur J Pharm Sci. 2020;6:77.
Alshehri S, Imam SS, Hussain A, Altamimi MA, Alruwaili NK, Alotaibi F, et al. Potential of solid dispersions to enhance solubility, bioavailability, and therapeutic efficacy of poorly water-soluble drugs: newer formulation techniques, current marketed scenario and patents. Drug Deliv. 2020;27(1):1625-1643.
Jagdale SK, Dehghan MH, Paul NS. Enhancement of Dissolution of Fenofibrate Using Complexation with Hydroxy Propyl β-Cyclodextrin. Turk J Pharm Sci. 2019;16(1):48-53
Patel H, Pandey N, Patel B, Ranch K, Bodiwala K, Vyas B. Enhancement of in vivo hypoglycemic effect of gliclazide by developing self microemulsifying pellet dosage form. Future J Pharm Sci. 2020;6:17.
Duong BH, Truong HN, Phan Nguyen QA, Nguyen Phu TN, Hong Nhan LT. Preparation of Curcumin Nanosuspension with Gum Arabic as a Natural Stabilizer: Process Optimization and Product Characterization. Processes. 2020;8:970.
Borkhataria C, Patel D, Bhagora S, Patel N, Patel K, Manek R. Study of homogenization on media milling time in preparation of irbesartan nanosuspension and optimization using design of experiments (DoE). Futur J Pharm Sci. 2020;6:87.
Jacob S, Nair AB, Shah J. Emerging role of nanosuspensions in drug delivery systems. Biomater Res. 2020;24:3.
Sattar A, Chen D, Jiang L, Pan Y, Tao Y, Huang L, Liu Z, Xie S, Yuan Z. Preparation, characterization and pharmacokinetics of cyadox nanosuspension. Sci Rep. 2017;7(1):2289.
Sinha B, Müller RH, Möschwitzer JP. Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size. Int J Pharm. 2013;453:126-141.
Gigliobianco MR, Casadidio C, Censi R, Di Martino P. Nanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability. Pharmaceutics. 2018;10(3):134.
Junyaprasert VB, Morakul B. Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs. Asian J Pharm Sci. 2015;10(1):13-23.
Melzig S, Niedbalka D, Schilde C, Kwade A. Spray drying of amorphous ibuprofen nanoparticles for the production of granules with enhanced drug release. Colloids Surf A Physicochem Eng. 2018;536:133-141.
Ma YQ, Zhang ZZ, Li G, Zhang J, Xiao HY, Li XF. Solidification drug nanosuspensions into nanocrystals by freeze-drying: a case study with ursodeoxycholic acid. Pharm Dev Technol. 2016;21(2):180-188.
Zhang X, Guan J, Ni R, Li LC, Mao S. Preparation and solidification of redispersible nanosuspensions. J Pharm Sci. 2014;103(7):2166-2176.
Butler EN, Kelly SP, Coupland VH, Rosenberg PS, Cook MB. Fatal prostate cancer incidence trends in the United States and England by race, stage, and treatment. Br J Cancer. 2020;123:487-494.
Saad F. Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer. Ther Adv Urol. 2013;5(4):201-10.
McKay RR, Kwak L, Crowdis JP, Sperger JM, Zhao SG, Xie W, Werner L, Lis RT, Zhang Z, Wei XX, Lang JM, Van Allen EM, Bhatt RS, Yu EY, Nelson PS, Bubley GJ, Montgomery RB, Taplin ME. Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. Clin Cancer Res. 2021;27(13):3610-3619.
Wilson VR, Lou X, Osterling DJ, Stolarik DF, Jenkins GJ, Nichols BLB, Dong Y, Edgar KJ, Zhang GGZ, Taylor LS. Amorphous solid dispersions of enzalutamide and novel polysaccharide derivatives: investigation of relationships between polymer structure and performance. Sci Rep. 2020;10:18535.
Nagaraj K, Narendar D, Kishan V. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability. Drug Dev Ind Pharm. 2017;43(7):1186-1196.
Li W, Yang Y, Tian Y, Xu X, Chen Y, Mu L, Zhang Y, Fang L. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension. Int J Pharm. 2011;408(1-2):157-162.
Aghrbi I, Fülöp V, Jakab G, Kállai-Szabó N, Balogh E, Antal I. Nanosuspension with improved saturated solubility and dissolution rate of cilostazol and effect of solidification on stability. J Drug Del Sci Technol. 2021;61:102165.
Khan A, Iqbal Z, Shah Y, Ahmad L, Ismail, Ullah Z, Ullah A. Enhancement of dissolution rate of class II drugs (Hydrochlorothiazide); a comparative study of the two novel approaches; solid dispersion and liqui-solid techniques. Saudi Pharm J. 2015; 23(6):650-657.
Kassem MAA, ElMeshad AN, Fares AR. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design. AAPS PharmSciTech. 2016;18(4):983-996.
Sharma M, Mehta I. Surface Stabilized Atorvastatin Nanocrystals with Improved Bioavailability, Safety and Antihyperlipidemic Potential. Sci Rep. 2019; 9(1):1-11.
Published
Abstract Display: 563 
PDF Downloads: 545 
